Literature DB >> 30414169

Demographic trends and KRAS/BRAFV600E mutations in colorectal cancer patients of South China: A single-site report.

Xinhui Fu1,2,3, Yan Huang3, Xinjuan Fan3, Yanhong Deng4, Huanliang Liu1,2, Hongzhi Zou1,2, Peihuang Wu1,2, Zhiting Chen1,2,3, Jinglin Huang1,2,3, Jingxuan Wang1,2, Hanjie Lin1,2,3, Shuhui Huang3, Xiaoli Tan1,2,3, Ping Lan1,5, Lei Wang5, Jian-Ping Wang1,2.   

Abstract

The incidence of colorectal cancer (CRC) is increasing in China. Here, we aimed to evaluate the latest demographic trends and KRAS/BRAF mutations status of Chinese CRC. Five thousand five hundred and forty-six CRC patients diagnosed from 2010 to 2017 were involved. KRAS exon 2 and BRAFV600E mutations were detected by Sanger sequencing and high-resolution melting analysis or allelic-specific probe method. Gene mutation profiles and clinicopathologic characteristics of 5495 patients were analyzed. The joinpoint regression model was used to predict the demographic data in 2018. We found KRAS exon 2 and BRAFV600E mutation rates were 37.7 and 2.8% in CRC patients. Tumors with KRAS exon 2 mutations were more likely to be present in female and patients aged older than 75 years, right colon and have well-differentiated histology. Tumors with BRAFV600E mutations were more likely to be present in the female, right colon and have poorly differentiated histology. From 2010 to 2017, the percentage of colon cancer and tubular adenocarcinoma in CRC increased substantially (from 39.3 to 51.8%, from 78.6 to 93.4%, respectively). The percentage of right colon cancer increased from 18.3 to 20.5%, which predictively may keep at 22.6% in 2018. The rise trends for patients with moderate differentiation tumor or KRAS exon 2 mutated tumor were apparent (from 50.3 to 78.6%, from 32.8 to 39.7%, respectively). In conclusion, in recent 8 years, there is a shift to the colon, especially right colon in the incidence of Chinese CRC. Moreover tubular adenocarcinoma is becoming the primary histology type.
© 2018 UICC.

Entities:  

Keywords:  zzm321990BRAF mutation; zzm321990KRAS mutation; colorectal cancer; demographic trends; tubular adenocarcinoma

Mesh:

Substances:

Year:  2019        PMID: 30414169     DOI: 10.1002/ijc.31973

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.

Authors:  Xiao-Na Chang; Fu-Mei Shang; Hong-Yu Jiang; Chen Chen; Zhe-Yan Zhao; Sheng-He Deng; Jun Fan; Xiao-Chuan Dong; Ming Yang; Yan Li; Kai-Lin Cai; Li Liu; Hong-Li Liu; Xiu Nie
Journal:  Curr Med Sci       Date:  2021-02-13

2.  A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population.

Authors:  Hafeez Afolabi; Salzihan Md Salleh; Zaidi Zakaria; Ch'ng Ewe Seng; Siti Norasikin Binti Mohd Nafil; Ahmad Aizat Bin Abdul Aziz; Yusuf Wada; Ahmad Irekeola
Journal:  Biomed Res Int       Date:  2022-06-23       Impact factor: 3.246

3.  Mps1 is associated with the BRAFV600E mutation and predicts poor outcome in patients with colorectal cancer.

Authors:  Yanyan Zhang; Jinyao Dong; Ruyi Shi; Liguo Feng; Yike Li; Caixia Cheng; Ling Zhang; Bin Song; Yanghui Bi; He Huang; Pengzhou Kong; Jiansheng Guo; Jing Liu
Journal:  Oncol Lett       Date:  2019-01-14       Impact factor: 2.967

4.  Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases.

Authors:  Yaolin Song; Lili Wang; Wenwen Ran; Guangqi Li; Yujing Xiao; Xiaonan Wang; Li Zhang; Xiaoming Xing
Journal:  Front Genet       Date:  2020-02-25       Impact factor: 4.599

5.  Nomograms for Prediction of Molecular Phenotypes in Colorectal Cancer.

Authors:  Zhuojun Yu; Huichuan Yu; Qi Zou; Zenghong Huang; Xiaolin Wang; Guannan Tang; Liangliang Bai; Chuanhai Zhou; Zhuokai Zhuang; Yumo Xie; Heng Wang; Gaopo Xu; Zijian Chen; Xinhui Fu; Meijin Huang; Yanxin Luo
Journal:  Onco Targets Ther       Date:  2020-01-13       Impact factor: 4.147

6.  KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: A single-site report.

Authors:  Qianxin Luo; Dianke Chen; Xinjuan Fan; Xinhui Fu; Tenghui Ma; Daici Chen
Journal:  Transl Oncol       Date:  2020-09-16       Impact factor: 4.243

7.  The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients.

Authors:  Xinhui Fu; Hanjie Lin; Xinjuan Fan; Yaxi Zhu; Chao Wang; Zhiting Chen; Xiaoli Tan; Jinglin Huang; Yacheng Cai; Yan Huang
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

8.  LINC00491 as a new molecular marker can promote the proliferation, migration and invasion of colon adenocarcinoma cells.

Authors:  Jiahui Wan; Daiqian Deng; Xiuli Wang; Xiaojin Wang; Shijun Jiang; Rongjun Cui
Journal:  Onco Targets Ther       Date:  2019-08-13       Impact factor: 4.147

9.  Identification of key candidate genes for colorectal cancer by bioinformatics analysis.

Authors:  Zhihua Chen; Yilin Lin; Ji Gao; Suyong Lin; Yan Zheng; Yisu Liu; Shao Qin Chen
Journal:  Oncol Lett       Date:  2019-10-17       Impact factor: 2.967

10.  RecQ-like helicase 4 (RECQL4) exacerbates resistance to oxaliplatin in colon adenocarcinoma via activation of the PI3K/AKT signaling pathway.

Authors:  Fei Zhou; Leiming Wang; Kangpeng Jin; Yang Wu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.